Core Viewpoint - Puxi Pharmaceutical Technology Co., Ltd. has submitted an IPO application to the Hong Kong Stock Exchange, marking a significant step in its capital journey after withdrawing its application from the Beijing Stock Exchange just three months prior [2][3]. Company Overview - Founded in 2016, Puxi Pharmaceutical focuses on the immune inflammation sector and is recognized as a national-level "specialized and innovative" enterprise. The company positions itself as a leader in localized targeted therapy, with over 60% of its workforce dedicated to research and development [3][8]. - The company has obtained 33 invention patents and achieved a post-investment valuation of 1.806 billion yuan after its latest financing round in December 2024 [3]. Financial Status - Puxi Pharmaceutical has not yet achieved commercial revenue, but it received government subsidies amounting to 112 million yuan and 1.158 million yuan in the first three quarters of 2024 and 2025, respectively [5]. - The company recorded net losses of 178 million yuan and 125 million yuan in the first three quarters of 2024 and 2025, with nearly 80% of its expenditures allocated to research and development [6]. - As of September 2025, the company had cash and cash equivalents of only 155 million yuan, which may not sustain normal operations for a year at the current burn rate [7]. Market Potential - The immune inflammation market is a blue ocean with significant growth potential, being the third-largest chronic disease market globally. The global market for autoimmune disease drugs is expected to reach 217 billion USD by 2033, while the allergic disease market is projected to reach 131.1 billion USD [9]. - In China, the market for these two sectors is expected to grow to 219.6 billion yuan and 293.8 billion yuan by 2033, with over 75 million and 250 million patients suffering from atopic dermatitis and allergic rhinitis, respectively [9]. Product Pipeline - Puxi Pharmaceutical's core product, Pumeixin (PG-011), has completed Phase III clinical trials for its gel formulation for atopic dermatitis and is in Phase III trials for its nasal spray for allergic rhinitis. The company has multiple products in development targeting various conditions, including pruritus, kidney disease, and glaucoma [3][10]. Competitive Advantages - The localized delivery method of Pumeixin is expected to minimize systemic side effects, providing a competitive edge, especially among mild to moderate patients and children [10]. - As a domestic company, Puxi Pharmaceutical has natural advantages in pricing and market access, particularly as it approaches commercialization of its core product [10]. Challenges and Risks - The company faces significant risks, including the uncertainty of regulatory approval for Pumeixin, which has completed Phase III trials but may require additional data for pediatric patients [11]. - Commercialization challenges are also present, as the company lacks a sales team and plans to rely on a Chief Sales Officer (CSO) partnership, which has a low success rate [11]. - Financial pressures are a concern, as the IPO fundraising scale has not been disclosed, and if it falls short of expectations, the company may face cash flow issues [12].

Core Viewpoint - The recent surge in pharmaceutical companies applying for listings on the Hong Kong Stock Exchange (HKEX) reflects a trend towards "A+H" dual-platform listings, which enhances financing channels and supports the domestic innovation of drugs and high-end medical devices [1][2][5][8]. Group 1: Listing Trends - Approximately 25 pharmaceutical companies have submitted listing applications to HKEX in September alone, with many already listed on A-shares, indicating a clear trend towards "A+H" dual-platform strategies [2][5]. - Notable companies such as Huaheng Biological and Baile Tianheng have recently applied for H-share listings, aiming to deepen their global strategic layout and enhance international financing capabilities [2][4]. Group 2: Industry Impact - The influx of companies seeking to list in Hong Kong is expected to accelerate industry consolidation, concentrating resources among financially robust listed companies and strengthening their market positions [4][8]. - Capital influx from these listings is anticipated to promote rapid development of innovative drugs and technologies, allowing companies to invest more in high-risk R&D projects, thereby improving overall industry innovation efficiency [4][8]. Group 3: Market Conditions - The favorable conditions for pharmaceutical companies include the advantages of the HKEX listing system, particularly the 18A listing rules introduced in 2018, which provide a pathway for unprofitable biotech companies to go public [5][8]. - The increasing demand for healthcare driven by population aging and accelerated regulatory approvals from domestic drug authorities create a conducive environment for pharmaceutical growth [5][8]. Group 4: Financial Performance - Many companies applying for listings are currently unprofitable, such as Maike Aote and its subsidiary Lanacheng, which reported significant losses during their respective financial periods [7][8]. - Financial data indicates that Maike Aote's R&D expenditures for 2023-2025 are projected to be approximately 87.01 million, 107 million, and 40.43 million yuan, with corresponding losses of about 195 million, 157 million, and 49.9 million yuan [7].

Core Viewpoint - He Mei Pharmaceutical is seeking to list on the Hong Kong Stock Exchange under the 18A chapter, aiming to attract capital for its development of small molecule drugs targeting autoimmune diseases and tumors, despite currently having no revenue or profit [1][3]. Group 1: Company Overview - He Mei Pharmaceutical was established in 2002 and focuses on developing small molecule drugs for autoimmune diseases and tumors, with a strong position in the industry [1]. - The company is developing seven small molecule drug candidates, all in clinical stages, and relies on government subsidies and financing for sustainable operations [1][3]. Group 2: Financial Performance - In 2023 and 2024, He Mei Pharmaceutical reported other income of approximately 4.05 million and 5.298 million RMB, respectively, primarily from government subsidies [3][4]. - The company incurred losses of approximately 156 million and 123 million RMB in the same periods, with significant expenditures in research and development [3][4]. Group 3: Product Pipeline - The core product, Mufemilast, is a novel small molecule PDE4B inhibitor, currently undergoing critical clinical trials for various indications, including psoriasis and Behçet's disease [5][6]. - Mufemilast is positioned as a unique drug with a dual mechanism of action, potentially reducing central nervous system side effects [6][7]. Group 4: Market Potential - The psoriasis drug market in China is projected to grow from 13.9 billion RMB in 2023 to 89.4 billion RMB by 2032, with a compound annual growth rate of 59.1% from 2023 to 2032 [7]. - He Mei Pharmaceutical is preparing for comprehensive clinical development of Mufemilast across eight major indications, indicating a strategic approach to capture market share [10][11]. Group 5: Competitive Landscape - The market for psoriasis treatments is becoming increasingly competitive, with major pharmaceutical companies also developing small molecule targeted therapies [10]. - He Mei Pharmaceutical's limited industry influence and recognition may pose challenges in differentiating its products in a crowded market [10][11].